A PYMNTS Company

China Watchdog Fines Two Pharma Firms

By  |  May 30, 2023

According to Reuters, two pharmaceutical companies were fined by China’s market regulator for engaging in monopolistic behavior.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Grand Pharmaceutical was fined 136 million yuan ($19.68 million) and had 149 million yuan of “illegal revenue” confiscated for engaging in a monopolistic agreement with Wuhan Healthcare Pharmaceuticals.

    Related: UK: CMA accuses pharma firms of market allocation

    Wuhan Healcare Pharmaceuticals was fined 4.13 million yuan by the regulator and had slightly over 30 million yuan of its revenue confiscated.

    In recent months, Chinese regulatory authorities have initiated antitrust investigations on various sectors, with a particular focus on technology corporations, including Alibaba Group.